Facebook Reveals Real-World GLP-1 Drug Side Effects: Social Media Pharmacovigilance

What the researchers found

Analysis of Facebook mentions of GLP-1 drug adverse events captures patient-reported side effects not fully represented in clinical trials or formal reporting systems.

Why it matters

These findings have practical implications for the growing number of patients using peptide-based therapies.

The numbers in context

Facebook posts analyzed from 2022-2024, tracking adverse event trends and co-occurrence patterns over the period of rapid GLP-1 drug adoption.

How the study worked

Study methodology detailed in the full publication.

Who was studied

Facebook users discussing GLP-1 RA weight loss medications from 2022-2024

What this study cannot tell us

Study limitations in the full publication.

How to read the evidence

Evidence level based on study design in publication.

When this study was published

Published in 2025.

The bigger picture

This study contributes to the expanding evidence for peptide therapeutics in clinical practice.

Questions still open

• What are the long-term implications?
• How do results compare to other evidence?
• What further research is needed?

Common questions

Read the original research

Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.

JMIR infodemiology, 5, e73619

Citation

Alibilli, Amrutha S; Jain, Vidur; Mane, Heran; Yue, Xiaohe; Ratzki-Leewing, Alexandria; Merchant, Junaid S; Criss, Shaniece; Nguyen, Quynh C; McCoy, Rozalina G; Nguyen, Thu T. (2025). Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.. JMIR infodemiology, 5, e73619. https://doi.org/10.2196/73619